GSK seeks clearance to acquire Pfizer’s consumer healthcare business
Published08 Mar 2019
The Commerce Commission has received a clearance application from GlaxoSmithKline plc seeking clearance to acquire the consumer healthcare business of Pfizer Inc.
GSK is a global pharmaceuticals company active in the research, development, manufacturing and supply of prescription pharmaceuticals, human vaccines, and consumer healthcare pharmaceuticals that are available without a prescription.
Pfizer is also a global pharmaceuticals company involved in the research, development, manufacturing and supply of medicines. Pfizer’s consumer healthcare business develops, manufactures and supplies non-prescription medicines in the areas of pain management, gastrointestinal health, respiratory, dietary supplements and personal care products.
In New Zealand, both parties supply non-prescription cold and flu treatments and medicines for systemic pain relief.
A public version of the clearance application is available on the Commission’s case register.
We will give clearance to a proposed merger if we are satisfied that the merger is unlikely to have the effect of substantially lessening competition in a market.
Further information explaining how the Commission assesses a merger application is available on our website.